{
    "clinical_study": {
        "@rank": "151279", 
        "arm_group": [
            {
                "arm_group_label": "Group A: \"age\"", 
                "arm_group_type": "Active Comparator", 
                "description": "Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was \u226435 years or 225 IU of rFSH if female age was \u2265 36 years."
            }, 
            {
                "arm_group_label": "Group B: \"nomogram\"", 
                "arm_group_type": "Experimental", 
                "description": "Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized controlled trial has been designed for carrying out  a comparison of new AMH\n      (Anti-M\u00fcllerian Hormone)-based individualized treatment (using a nomogram) with the wide\n      accepted age-based strategy. The main objective of the trial is to assess whether an\n      individualized FSH starting dose can increase the rate of women with an adequate ovarian\n      response in terms of retrieved oocytes (optimal number of retrieved oocytes: 5-14)."
        }, 
        "brief_title": "Age- Versus Ovarian Reserve Markers - Based Therapy in In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles", 
        "condition": [
            "In Vitro Fertilization", 
            "Ovarian Stimulation"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  first or second IVF/ICSI attempt (the second one after 6 months from the   first\n             one);regular menstrual cycles (25-33 days);female age \u2264 40; day 3 FSH \u2264\n             15IU/L;treatment with a long GnRH agonist protocol (buserelin)+rFSH;BMI: >18 and \u2264 25\n             kg/m2;presence of both ovaries.\n\n        Exclusion Criteria:\n\n          -  irregular cycles, anovulatory infertility, endometriosis III-IV stage AFS, use of\n             adjunctive therapies for stimulation, evidence of PCO status, previous ovarian\n             surgery,  presence of ovarian cysts, history of PID, use of hormonal contraception in\n             the previous 3 months, any known metabolic or endocrinological disease, AMH levels <\n             1 and > 4.0 ng/ml"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816789", 
            "org_study_id": "ANDROS-01-13"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A: \"age\"", 
                    "Group B: \"nomogram\""
                ], 
                "intervention_name": "rFSH", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A: \"age\"", 
                    "Group B: \"nomogram\""
                ], 
                "intervention_name": "buserelin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Buserelin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Starting dose", 
            "rFSH", 
            "controlled", 
            "ovarian", 
            "stimulation", 
            "IVF/ICSI", 
            "cycles"
        ], 
        "lastchanged_date": "March 22, 2013", 
        "location": {
            "contact": {
                "email": "marino@centroandros.it", 
                "last_name": "Adolfo Allegra, MD", 
                "phone": "+39 091 6785537"
            }, 
            "facility": {
                "address": {
                    "city": "Palermo", 
                    "country": "Italy", 
                    "state": "Sicily", 
                    "zip": "90144"
                }, 
                "name": "ANDROS Day Surgery Clinic"
            }, 
            "investigator": {
                "last_name": "Adolfo Allegra, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "allegra@centroandros.it", 
            "last_name": "Adolfo Allegra, MD", 
            "phone": "+39 091 6785537"
        }, 
        "overall_contact_backup": {
            "email": "marino@centroandros.it", 
            "last_name": "Angelo Marino, MD", 
            "phone": "+39 091 6785537"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Istituto Superiore di Sanit\u00e0"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The percentage of women with an appropriate number (N=5-14) of retrieved oocytes in IVF/ICSI cycles", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816789"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Andros Day Surgery Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Andros Day Surgery Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}